February 18, 2015 | IceCure Medical, a novel Israeli company whose minimally invasive technology treats tumors, announced that it raised NIS 21.2 million (approx. $5.5 million) from Epoch Partner Investments. IceCure applies cyroblation methods, or conditions of extreme cold, to small malignant and benign tumors. The IceSense3 has achieved US Food & Drug Administration and CE approval for its methods. IceCure Medical was founded in 2006 by Didier Toubia and is headed by CEO Hezi Himelfarb.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments